Chronic Disease Management Brief

Chronic Disease Management Brief

공개
NeoDrop Official
NeoDrop Official

Weekly translation of the latest diabetes / cardiovascular / liver disease management guidelines into everyday language

Chronic Disease Management Brief
Chronic Disease Management Brief

Your Heart, Kidneys, and Liver Are One System Now

A landmark 2026 multi-society guideline from AHA/ACC/ADA/ASN formally defines cardiovascular-kidney-metabolic (CKM) syndrome and asks doctors to manage heart disease, kidney disease, and metabolic conditions as one connected system. This week also covers two oral GLP-1 pills — orforglipron (Foundayo) and elecoglipron — publishing major Phase 2b/3 trial data advancing toward FDA review, the FDA clearing Dexcom Stelo as the first OTC continuous glucose monitor for children aged 2+, and a PROMISE trial analysis showing fatty liver raises major heart event risk 1.7-fold via noncalcified plaque that a clean calcium score can miss.

Chronic Disease Management Brief
Chronic Disease Management Brief

ADA 2026 Recap: What the Biggest Diabetes Meeting of the Year Means for Your Health

The ADA's 86th Scientific Sessions in New Orleans produced landmark shifts in diabetes care: heart and kidney protection is now a co-equal goal alongside blood sugar control, CGMs are proven to help non-insulin type 2 patients, a 29% heart event reduction from Repatha in high-risk diabetics, and four next-generation weight-loss drugs with remarkable Phase 3 data. Plus cardiovascular and liver disease updates.

Chronic Disease Management Brief
Chronic Disease Management Brief

Weekly health update: June 1, 2026

This week covers all three disease areas: in diabetes, the FDA approved needle-free inhaled insulin (Afrezza) for children, and a two-year trial showed tirzepatide keeps 60% of early type-2 patients at normal blood sugar. In cardiovascular, the AHA confirmed exercise protects your heart regardless of weight loss, updated hypertension stats show 47% of US adults are affected, and a NEJM gene-editing trial cut LDL by up to 62% with one infusion. In liver disease, the FDA approved the first-ever hepatitis D treatment, Phase 3 data shows a functional cure rate of up to 26% for hepatitis B, and 35 international guidelines agree on 7–10% weight loss as the key target for fatty liver disease.

전체 콘텐츠 아카이브 보기더 많은 채널 찾기